Ebola Protein Blocks Early Step in Body's Counterattack on Virus

Comments
Posted in News, Ebola Virus, Research
Print

One of the human body’s first responses to a viral infection is to make and release signaling proteins called interferons, which amplify the immune system response to viruses. Over time, many viruses have evolved to undermine interferon’s immune-boosting signal, and a paper published today in the journal Cell Host & Microbe describes a mechanism unique to the Ebola virus that defeats attempts by interferon to block viral reproduction in infected cells.

The newly published study explains for the first time how the production by the virus of a protein called Ebola Viral Protein 24 (eVP24) stops the interferon-based signals from ramping up immune defenses. With the body’s first response disabled, the virus is free to mass produce itself and trigger the too-large immune response that damages organs and often becomes deadly as part of Ebola virus disease (EVD).

The study was led by scientists from Washington University School of Medicine in St. Louis in collaboration with researchers from the Icahn School of Medicine at Mount Sinai and the University of Texas Southwestern Medical Center.

“Our study is the first to show how Ebola viral protein 24 defeats the signal sent by interferons, the key signaling molecules in the body’s early response to Ebola virus infection,” says Christopher F. Basler, PhD, professor of microbiology at the Icahn School of Medicine at Mount Sinai, and an author of the newly published paper. “These newfound details of Ebola biology are already serving as the foundation of a new drug development effort, albeit in its earliest stages,” adds Basler, who is also a researcher within the Mount Sinai Global Health and Emerging Pathogens Institute.

“We’ve known for a long time that infection with Ebola virus obstructs an important arm in our immune system that is activated by molecules called interferons,” says senior author Gaya Amarasinghe, PhD, assistant professor of pathology and immunology at Washington University School of Medicine in St. Louis. “By determining the structure of an eVP24 in complex with a cellular transporter, we learned how Ebola does this.

The study spotlights the part of the body’s defense system that fights infection called innate immunity, the mix of proteins and cells that most quickly recognizes an invasion by a virus. This part of immunity keeps a virus from quickly reproducing inside cells.

To trigger an effective, early response to viral infection, interferons must pass on their signal to other cells. This occurs through other messengers inside cells as part of interferon signaling pathways, with the last of these messengers turning on genes inside the nuclei of cells to drive the immune response.

The current study determined the structure of eVP24 when bound to its cellular targets, transport proteins called karyopherins. The study used these structures to show how, in place of interferon’s natural downstream signal carrier phosphorylated STAT1, eVP24 docks into the karyopherins meant to escort STAT1 into cell nuclei where it turns on interferon-targeted genes. By elegantly interfering at this stage, eVP24 cripples innate immunity to cause EVD.

In 2006, Basler and colleagues found that the Ebola virus suppresses the human immune response through eVP24, but not how. Through of combination of molecular biology techniques, cell studies and tests that reveal protein structures, the current team led by Amarasighe defined the molecular basis for how eVP24 achieves this suppression.

Understanding exactly how the Ebola virus targets the interferon pathway could help guide drug development moving forward. Basler describes how it may be possible to find an antibody or molecule that interferes with eVP24, or that works around its competition with STAT1, such that treatment of patients with extra interferon, long used against the hepatitis C virus for instance, might become useful against the Ebola virus.

“We feel the urgency of the present situation, but still must do the careful research to ensure that any early drug candidates against the Ebola virus are proven to be safe, effective and ready for use in future outbreaks,” says Basler, who is also principal investigator of an NIH-funded Center of Excellence for Translational Research (CETR) focused on developing drugs to treat Ebola virus infections.

Along with Amarasinghe and Basler, the study was also conducted by Wei Xu, Joshua Alinger, Kayla Berry and Daisy Leung from the Department of Pathology and Immunology; and by Tom Brett in the Department of Internal Medicine, all within the Washington University School of Medicine in St. Louis. Anuradha Mittal in the Department of Biomedical Engineering at Washington University was also an author. Megan Edwards, Alicia Feagins, Benjamin Yen, and Jennifer Hamilton in the Department of Microbiology within the Icahn School of Medicine at Mount Sinai were also authors on the study, along with Dominika Borek in the departments of Biophysics and Biochemistry, University of Texas Southwestern Medical Center at Dallas.

The study was funded in part by grants from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

Source: Mount Sinai Health System

Comments
comments powered by Disqus